The sale is part of Novo Nordisk’s proposed acquisition of Catalent, a contract development and manufacturing organization based in Somerset, N.J. The three facilities are in Italy, Belgium and Bloomington, Ind., and employ more than 3,000 people, according to a Feb. 5 news release.
The facilities are equipped for sterile filling, and Novo Nordisk said the fill-finish sites will focus on increasing supply of its diabetes and obesity treatments starting in 2026.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
